BIOSPECIFICS TECHNOLOGIES CORP Form 8-K March 01, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): February 25, 2013

BIOSPECIFICS TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

<u>Delaware</u>

<u>001-34236</u>

11-3054851

(State or Other Jurisdiction Of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

35 Wilbur Street Lynbrook, NY 11563

(Address of Principal Executive Office) (Zip Code)

516.593.7000

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation	on of
the registrant under any of the following provisions:	
[] Written communications numerous to Pula 425 under the Securities Act (17 CEP 220 425)	

[_]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[_] -2(b)	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d)
[_]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

INTRODUCTORY COMMENT

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technolo Corp.

ITEM 8.01 OTHER EVENTS

The Board of Directors of the Company has set June 19, 2013 as the date of the 2013 Annual Meeting of Stockholders (the <u>Annual Meeting</u>). The Annual Meeting will be held at the New York offices of Bingham McCutchen LLP, located at 399 Park Avenue, New York, New York 10022. Stockholders of record as of the close of business on April 23, 2013 will be eligible to vote at the Annual Meeting.

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 28, 2013 BIOSPECIFICS TECHNOLOGIES CORP.

(Registrant)

/s/ Thomas L. Wegman

Thomas L. Wegman President